反应详情

The title compound was prepared following the procedure as described for Example-1 using 2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxylic acid (Intermediate-3, 0.070 g, 0.177 mmol), benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (0.157 g, 0.355 mmol), N-methyl morpholine (0.5 mL), DMF (1.0 mL), THF (5.0 mL) and 4-bromo aniline (0.092 g, 0.531 mmol) to afford 0.010 g of the desired product. 1HNMR (DMSO-d6): δ 1.23 (s, 3H), 1.57 (s, 3H), 3.06 (s, 2H), 7.24 (s, 1H), 7.52 (d, J=8.7 Hz, 2H), 7.68 (d, J=8.7 Hz, 2H), 8.44 (s, 2H), 9.72 (s, 1H), 10.98 (s, 1H), 11.52 (s, 1H); MS [M−H]−: 546.22.

1. customThe title compound was prepared